Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.

Ghaemmaghami F, Karimi-Zarchi M, Modares-Gilani M, Mousavi A, Behtash N.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):719-24.

2.

Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.

Taşkın S, Güngör M, Ortaç F, Öztuna D.

Arch Gynecol Obstet. 2013 Dec;288(6):1399-403. doi: 10.1007/s00404-013-2924-7. Epub 2013 Jun 18.

PMID:
23775264
3.

Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.

Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.

Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.

PMID:
27916269
4.

Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma.

Giannopoulos T, Butler-Manuel S, Taylor A, Ngeh N, Thomas H.

Eur J Gynaecol Oncol. 2006;27(1):25-8.

PMID:
16550963
5.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
6.

Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.

Bian C, Yao K, Li L, Yi T, Zhao X.

Arch Gynecol Obstet. 2016 Jan;293(1):163-8. doi: 10.1007/s00404-015-3813-z. Epub 2015 Jul 22.

PMID:
26198168
7.

Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?

Markauskas A, Mogensen O, dePont Christensen R, Jensen PT.

Int J Gynecol Cancer. 2014 Oct;24(8):1420-8. doi: 10.1097/IGC.0000000000000241.

PMID:
25180461
8.

Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients.

Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, Scambia G.

Oncology. 2003;65(4):316-22.

PMID:
14707451
9.

Outcome of interval debulking in advanced ovarian cancer patients.

Suprasert P, Tiyanon J, Kietpeerakool C.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):519-24.

10.

Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.

Matsuhashi T, Takeshita T, Yamamoto A, Kawase R, Yamada T, Kurose K, Doi D, Konnai K, Onose R, Kato H.

J Nippon Med Sch. 2017;84(4):170-176. doi: 10.1272/jnms.84.170.

11.

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.

Luo Y, Lee M, Kim HS, Chung HH, Song YS.

Medicine (Baltimore). 2016 Sep;95(36):e4797. doi: 10.1097/MD.0000000000004797.

12.

Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?

Solmaz U, Mat E, Dereli ML, Turan V, Peker N, Tosun G, Dogan A, Adiyeke M, Ozdemir A, Gungorduk K, Sanci M, Yildirim Y.

J BUON. 2015 May-Jun;20(3):847-54.

PMID:
26214639
13.

Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.

Favero G, Macerox N, Pfiffer T, Köhler C, da Costa Miranda V, Estevez Diz Mdel P, Fukushima JT, Baracat EC, Carvalho JP.

Oncology. 2015;89(3):159-66. doi: 10.1159/000381462. Epub 2015 May 1.

PMID:
25968072
14.

Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.

Ren Y, Shi T, Jiang R, Yin S, Wang P, Zang R.

Int J Gynecol Cancer. 2015 Oct;25(8):1398-404. doi: 10.1097/IGC.0000000000000517.

PMID:
26222486
16.

Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.

Loizzi V, Leone L, Camporeale A, Resta L, Selvaggi L, Cicinelli E, Cormio G.

Oncology. 2016;91(4):211-216. Epub 2016 Aug 3. Review.

PMID:
27487241
17.
18.

Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?

Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H.

Eur J Cancer. 2012 Sep;48(14):2146-54. doi: 10.1016/j.ejca.2012.01.031. Epub 2012 Feb 28.

PMID:
22382201
19.

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.

Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS.

Gynecol Oncol. 2013 Apr;129(1):63-8. doi: 10.1016/j.ygyno.2013.01.009. Epub 2013 Jan 18.

PMID:
23337490
20.

Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.

Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, Wakabayashi M, Takehara K, Saito M, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Takeshima N, Watanabe Y, Yaegashi N, Konishi I, Kamura T, Yoshikawa H; Japan Clinical Oncology Group.

Eur J Cancer. 2016 Sep;64:22-31. doi: 10.1016/j.ejca.2016.05.017. Epub 2016 Jun 17.

PMID:
27323348

Supplemental Content

Support Center